Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2021 and 2022
October 25, 2021 at 04:16 pm EDT
Share
Medpace Holdings, Inc. provided earnings guidance for the year 2021 and 2022. For the year 2021, the company expects revenue in the range of $1.135 billion to $1.145 billion, representing growth of 22.6% to 23.7% over 2020 revenue of $925.9 million. The company expected GAAP net income in the range of $176.0 million to $180.0 million. Based on forecasted 2021 revenue and GAAP net income, diluted earnings per share (GAAP) is forecasted in the range of $4.66 to $4.77.
For the year 2022, The Company forecasts revenue in the range of $1.400 billion to $1.460 billion.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
MEDPACE HOLDINGS, INC. 
